SÃ¸ren Nielsen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3889388/publications.pdf

Version: 2024-02-01

102	5,461	70961 41	88477 70
papers	citations	h-index	g-index

111	111	111	7583
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Isolation and Characterization of Human Brown Adipocytes. Methods in Molecular Biology, 2022, 2448, 217-234.	0.4	0
2	Localization of aquaglyceroporins in human and murine white adipose tissue. Histochemistry and Cell Biology, 2022, , 1.	0.8	4
3	Can we target obesity using a single-cell atlas of adipose tissue?. Med, 2022, 3, 276-278.	2.2	4
4	Endogenous Fatty Acid Synthesis Drives Brown Adipose Tissue Involution. Cell Reports, 2021, 34, 108624.	2.9	33
5	Lipolysis drives expression of the constitutively active receptor GPR3 to induce adipose thermogenesis. Cell, 2021, 184, 3502-3518.e33.	13.5	68
6	Increased lipolysis after infusion of acylated ghrelin: a randomized, doubleâ€blinded placeboâ€controlled trial in hypopituitary patients. Clinical Endocrinology, 2020, 93, 672-677.	1.2	3
7	Calsyntenin 3Î² Is Dynamically Regulated by Temperature in Murine Brown Adipose and Marks Human Multilocular Fat. Frontiers in Endocrinology, 2020, 11, 579785.	1.5	7
8	Human thermogenic adipocyte regulation by the long noncoding RNA LINC00473. Nature Metabolism, 2020, 2, 397-412.	5.1	65
9	Human brown adipose tissue is phenocopied by classical brown adipose tissue in physiologically humanized mice. Nature Metabolism, 2019, 1, 830-843.	5.1	103
10	Proteomics-Based Comparative Mapping of the Secretomes of Human Brown and White Adipocytes Reveals EPDR1 as a Novel Batokine. Cell Metabolism, 2019, 30, 963-975.e7.	7.2	109
11	Diverse repertoire of human adipocyte subtypes develops from transcriptionally distinct mesenchymal progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17970-17979.	3.3	106
12	Heterogeneity in the perirenal region of humans suggests presence of dormant brown adipose tissue that contains brown fat precursor cells. Molecular Metabolism, 2019, 24, 30-43.	3.0	85
13	Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes. Diabetologia, 2019, 62, 1251-1256.	2.9	43
14	TGF-Î²2 is an exercise-induced adipokine that regulates glucose and fatty acid metabolism. Nature Metabolism, 2019, 1, 291-303.	5.1	128
15	Metformin does not affect postabsorptive hepatic free fatty acid uptake, oxidation or resecretion in humans: A 3â€month placeboâ€controlled clinical trial in patients with type 2 diabetes and healthy controls. Diabetes, Obesity and Metabolism, 2018, 20, 1435-1444.	2.2	18
16	Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension. Scandinavian Journal of Rheumatology, 2018, 47, 319-324.	0.6	30
17	Brown Fat AKT2 Is a Cold-Induced Kinase that Stimulates ChREBP-Mediated De Novo Lipogenesis to Optimize Fuel Storage and Thermogenesis. Cell Metabolism, 2018, 27, 195-209.e6.	7.2	151
18	VLDL triglyceride accumulation in skeletal muscle and adipose tissue in type 2 diabetes. Current Opinion in Lipidology, 2018, 29, 42-47.	1.2	7

#	ARTICLE	IF	CITATIONS
19	Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 419-426.	2.2	8
20	Increased AQP7 abundance in skeletal muscle from obese men with type 2 diabetes. American Journal of Physiology - Endocrinology and Metabolism, 2018, 315, E367-E373.	1.8	13
21	Gamma-Aminobutyric Acid Signaling in Brown Adipose Tissue Promotes Systemic Metabolic Derangement in Obesity. Cell Reports, 2018, 24, 2827-2837.e5.	2.9	40
22	Cardiolipin Synthesis in Brown and Beige Fat Mitochondria Is Essential for Systemic Energy Homeostasis. Cell Metabolism, 2018, 28, 159-174.e11.	7.2	114
23	Single Cell Analysis Identifies the miRNA Expression Profile of a Subpopulation of Muscle Precursor Cells Unique to Humans With Type 2 Diabetes. Frontiers in Physiology, 2018, 9, 883.	1.3	5
24	No effect of resveratrol on VLDLâ€TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease. Diabetes, Obesity and Metabolism, 2018, 20, 2504-2509.	2.2	29
25	Metabolic regulation and the anti-obesity perspectives of human brown fat. Redox Biology, 2017, 12, 770-775.	3.9	62
26	Dysregulation of a novel miR-23b/27b-p53 axis impairs muscle stem cell differentiation of humans with type 2 diabetes. Molecular Metabolism, 2017, 6, 770-779.	3.0	27
27	Increased VLDL-TG Fatty Acid Storage in Skeletal Muscle in Men With Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 831-839.	1.8	14
28	Postprandial VLDL-TG metabolism in type 2 diabetes. Metabolism: Clinical and Experimental, 2017, 75, 25-35.	1.5	17
29	Alterations in Vascular Endothelial Growth Factors After Heart Transplantation. Journal of Heart and Lung Transplantation, 2017, 36, S395-S396.	0.3	0
30	Measuring VLDL1-Triglyceride and VLDL2-Triglyceride Kinetics in Men: Effects of Dietary Control on Day-to-Day Variability. Hormone and Metabolic Research, 2017, 49, 604-611.	0.7	2
31	Whole-Body Biodistribution, Dosimetry, and Metabolite Correction of [¹¹C]Palmitate: A PET Tracer for Imaging of Fatty Acid Metabolism. Molecular Imaging, 2017, 16, 153601211773448.	0.7	23
32	Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes. Diabetologia, 2016, 59, 833-843.	2.9	15
33	Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1637-1646.	1.8	26
34	Pre-training levels of testosterone and sex hormone-binding globulin are not correlated with training adaptations in fat mass and insulin sensitivity in healthy young men. Endocrine, 2016, 52, 660-663.	1.1	0
35	Lean body mass, not FFA, predicts VLDL-TG secretion rate in healthy men. Obesity, 2015, 23, 1379-1385.	1.5	7
36	Complete recovery after severe myxoedema coma complicated by status epilepticus. BMJ Case Reports, 2015, 2015, bcr2014209071-bcr2014209071.	0.2	5

#	ARTICLE	IF	CITATIONS
37	Isolated hyperglycaemia does not increase VLDL-triacylglycerol secretion in type 1 diabetic men. Diabetologia, 2015, 58, 355-362.	2.9	2
38	A mixed diet supplemented with <scp>l</scp>-arabinose does not alter glycaemic or insulinaemic responses in healthy human subjects. British Journal of Nutrition, 2015, 113, 82-88.	1.2	9
39	The miRNA Plasma Signature in Response to Acute Aerobic Exercise and Endurance Training. PLoS ONE, 2014, 9, e87308.	1.1	247
40	Novel nuances of human brown fat. Adipocyte, 2014, 3, 54-57.	1.3	33
41	Muscle specific miRNAs are induced by testosterone and independently upregulated by age. Frontiers in Physiology, 2014, 4, 394.	1.3	30
42	Ten weeks of aerobic training does not result in persistent changes in VLDL triglyceride turnover or oxidation in healthy men. European Journal of Endocrinology, 2014, 171, 603-613.	1.9	8
43	Kinetics and utilization of lipid sources during acute exercise and acipimox. American Journal of Physiology - Endocrinology and Metabolism, 2014, 307, E199-E208.	1.8	17
44	Acute changes in lipoprotein subclasses during exercise. Metabolism: Clinical and Experimental, 2014, 63, 61-68.	1.5	14
45	Endurance training enhances skeletal muscle interleukin-15 in human male subjects. Endocrine, 2014, 45, 271-278.	1.1	77
46	Independent Effects of Testosterone on Lipid Oxidation and VLDL-TG Production. Diabetes, 2013, 62, 1409-1416.	0.3	26
47	Whole body metabolic effects of prolonged endurance training in combination with erythropoietin treatment in humans: a randomized placebo controlled trial. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E879-E889.	1.8	28
48	Determinants of VLDL-triglycerides production. Current Opinion in Lipidology, 2012, 23, 321-326.	1.2	71
49	Estradiol acutely inhibits whole body lipid oxidation and attenuates lipolysis in subcutaneous adipose tissue: a randomized, placebo-controlled study in postmenopausal women. European Journal of Endocrinology, 2012, 167, 543-551.	1.9	34
50	Role of vitamin C and E supplementation on IL-6 in response to training. Journal of Applied Physiology, 2012, 112, 990-1000.	1.2	60
51	Impaired Insulinâ€Mediated Antilipolysis and Lactate Release in Adipose Tissue of Upperâ€Body Obese Women. Obesity, 2012, 20, 57-64.	1.5	14
52	Satellite Cells Derived from Obese Humans with Type 2 Diabetes and Differentiated into Myocytes In Vitro Exhibit Abnormal Response to IL-6. PLoS ONE, 2012, 7, e39657.	1.1	55
53	Acute Peripheral Metabolic Effects of Intraarterial Leg Infusion of Somatostatin in Healthy Young Men. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2581-2589.	1.8	7
54	Increased VLDL-Triglyceride Secretion Precedes Impaired Control of Endogenous Glucose Production in Obese, Normoglycemic Men. Diabetes, 2011, 60, 2257-2264.	0.3	37

#	ARTICLE	IF	CITATIONS
55	Basal and Insulin Mediated VLDL-Triglyceride Kinetics in Type 2 Diabetic Men. Diabetes, 2011, 60, 88-96.	0.3	48
56	Similar VLDL-TG Storage in Visceral and Subcutaneous Fat in Obese and Lean Women. Diabetes, 2011, 60, 2787-2791.	0.3	12
57	Effects of exercise on VLDL-triglyceride oxidation and turnover. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E939-E944.	1.8	46
58	Effect of antioxidant supplementation on insulin sensitivity in response to endurance exercise training. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E761-E770.	1.8	70
59	Reply to Russell: VLDL-TG kinetics: how to interpret a dual-isotope study. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E253-E253.	1.8	0
60	Antioxidant Supplementation Does Not Alter Endurance Training Adaptation. Medicine and Science in Sports and Exercise, 2010, 42, 1388-1395.	0.2	150
61	Postabsorptive VLDLâ€TG Fatty Acid Storage in Adipose Tissue in Lean and Obese Women. Obesity, 2010, 18, 1304-1311.	1.5	18
62	Muscle specific microRNAs are regulated by endurance exercise in human skeletal muscle. Journal of Physiology, 2010, 588, 4029-4037.	1.3	273
63	Acute estrogen exposure does not affect basal very low-density lipoproteinâ€“triglyceride production or oxidation in postmenopausal women. European Journal of Endocrinology, 2010, 163, 421-426.	1.9	6
64	Decreased Lipid Intermediate Levels and Lipid Oxidation Rates Despite Normal Lipolysis in Patients with Hypothyroidism. Thyroid, 2010, 20, 843-849.	2.4	19
65	Using molecular classification to predict gains in maximal aerobic capacity following endurance exercise training in humans. Journal of Applied Physiology, 2010, 108, 1487-1496.	1.2	296
66	Role of Antioxidant Supplementation on Training-induced IL-6. Medicine and Science in Sports and Exercise, 2010, 42, 20.	0.2	2
67	Fibroblast Growth Factor-21 Is Induced in Human Skeletal Muscles by Hyperinsulinemia. Diabetes, 2009, 58, 2797-2801.	0.3	177
68	Impact of body composition on very-low-density lipoprotein-triglycerides kinetics. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E165-E173.	1.8	28
69	VLDL-TG kinetics: a dual isotope study for quantifying VLDL-TG pool size, production rates, and fractional oxidation in humans. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E1324-E1330.	1.8	27
70	ROS and myokines promote muscle adaptation to exercise. Trends in Endocrinology and Metabolism, 2009, 20, 95-99.	3.1	132
71	Peroxisome proliferatorâ€activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. Clinical Endocrinology, 2008, 69, 452-461.	1.2	8
72	Exercise induces expression of leukaemia inhibitory factor in human skeletal muscle. Journal of Physiology, 2008, 586, 2195-2201.	1.3	101

#	ARTICLE	IF	CITATIONS
73	Calprotectin is released from human skeletal muscle tissue during exercise. Journal of Physiology, 2008, 586, 3551-3562.	1.3	48
74	Skeletal muscle as an immunogenic organ. Current Opinion in Pharmacology, 2008, 8, 346-351.	1.7	79
75	Acute Effects of Ghrelin Administration on Glucose and Lipid Metabolism. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 438-444.	1.8	79
76	Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E920-E927.	1.8	84
77	Simvastatin Reduces Plasma Osteoprotegerin in Type 2 Diabetic Patients With Microalbuminuria. Diabetes Care, 2007, 30, 3122-3124.	4.3	33
78	The Impact of Pegvisomant Treatment on Substrate Metabolism and Insulin Sensitivity in Patients with Acromegaly. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1724-1728.	1.8	94
79	Insulin dose response analysis of free fatty acid kinetics. Metabolism: Clinical and Experimental, 2007, 56, 68-76.	1.5	68
80	Visfatin mRNA expression in human subcutaneous adipose tissue is regulated by exercise. American Journal of Physiology - Endocrinology and Metabolism, 2007, 292, E24-E31.	1.8	61
81	Exercise induces interleukin-8 receptor (CXCR2) expression in human skeletal muscle. Experimental Physiology, 2007, 92, 233-240.	0.9	73
82	Motor cortical excitability remains unaffected of short-term hyperglycemia in Type 1 diabetic patients. Journal of Diabetes and Its Complications, 2006, 20, 51-55.	1.2	10
83	Measuring VLDL-triglyceride turnover in humans using ex vivo-prepared VLDL tracer. Journal of Lipid Research, 2006, 47, 99-106.	2.0	32
84	Free fatty acids decrease circulating ghrelin concentrations in humans. European Journal of Endocrinology, 2006, 154, 667-673.	1.9	41
85	Energy expenditure, insulin, and VLDL-triglyceride production in humans. Journal of Lipid Research, 2006, 47, 2325-2332.	2.0	34
86	Vascular Response to Angiotensin II in Upper Body Obesity. Hypertension, 2004, 44, 435-441.	1.3	30
87	Evidence of increased visceral obesity and reduced physical fitness in healthy insulin-resistant first-degree relatives of type 2 diabetic patients. European Journal of Endocrinology, 2004, 150, 207-214.	1.9	52
88	Muscle Strength in Type 2 Diabetes. Diabetes, 2004, 53, 1543-1548.	0.3	292
89	Effects of GH on urea, glucose and lipid metabolism, and insulin sensitivity during fasting in GH-deficient patients. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E737-E743.	1.8	36
90	Energy expenditure, sex, and endogenous fuel availability in humans. Journal of Clinical Investigation, 2003, 111, 981-988.	3.9	112

#	ARTICLE	IF	CITATIONS
91	Mortality in Concurrent Type 1 Diabetes and Anorexia Nervosa. Diabetes Care, 2002, 25, 309-312.	4.3	208
92	Eating disorders in females with type 1 diabetes: an update of a meta-analysis. European Eating Disorders Review, 2002, 10, 241-254.	2.3	110
93	Muscle mass and function in thyrotoxic patients before and during medical treatment. Clinical Endocrinology, 1999, 51, 693-699.	1.2	52
94	Collection and Interpretation of Plasma Leptin Concentration Data in Humans. Obesity, 1999, 7, 241-245.	4.0	26
95	Eating disorder and type 1 diabetes: overview and summing-up. European Eating Disorders Review, 1998, 6, 4-26.	2.3	26
96	Combination of enalapril and low-dose thiazide reduces normoalbuminuria in essential hypertension. Journal of Hypertension, 1998, 16, 1539-1544.	0.3	8
97	Glucose turnover, fuel oxidation and forearm substrate exchange in patients with thyrotoxicosis before and after medical treatment. Clinical Endocrinology, 1996, 44, 453-459.	1.2	29
98	Prorenin and renal function in NIDDM patients with normoâ€•and microalbuminuria. Journal of Internal Medicine, 1995, 238, 499-505.	2.7	8
99	Albuminuria and 24-h Ambulatory Blood Pressure in Normoalbuminuric and Microalbuminuric NIDDM Patients. A longitudinal study. Diabetes Care, 1995, 18, 1434-1441.	4.3	37
100	Systolic Blood Pressure Relates to the Rate of Decline of Glomerular Filtration Rate in Type II Diabetes. Diabetes Care, 1993, 16, 1427-1432.	4.3	62
101	Long-term bone loss in insulin-dependent diabetic patients with microvascular complications. The Journal of Diabetic Complications, 1990, 4, 145-149.	0.2	56
102	Validity of rapid estimation of erythrocyte volume in the diagnosis of polycytemia vera. European Journal of Nuclear Medicine and Molecular Imaging, 1989, 15, 32-7.	2.2	6